A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population

References

• Makris K , Spanou L . Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev . 2016;37(2):85–98.28303073
   PubMedGoogle Scholar
• Kellum JA , Sileanu FE , Murugan R , et al. Classifying AKI by urine output versus serum creatinine level. J Am Soc Nephrol . 2015;26(9):2231–2238. doi:10.1681/ASN.2014070724 25568178
   PubMed Web of Science ®Google Scholar
• Podkowińska A , Formanowicz D . Chronic kidney disease as oxidative stress- and inflammatory-mediated cardiovascular disease. Antioxidants . 2020;9(8):752–780. doi:10.3390/antiox9080752
   Web of Science ®Google Scholar
• Karasu E , Nilsson B , Köhl J , et al. Targeting complement pathways in polytrauma- and sepsis-induced multiple-organ dysfunction. Front Immunol . 2019;10:543–551. doi:10.3389/fimmu.2019.00543 30949180
   PubMed Web of Science ®Google Scholar
• Oliveros H , Buitrago G . Effect of renal support therapy on 5-year survival in patients discharged from the intensive care unit. J Intensive Care . 2020;8(1):63–75. doi:10.1186/s40560-020-00481-0 32832092
   PubMed Web of Science ®Google Scholar
• La Vignera S , Condorelli RA , Cannarella R , et al. Urogenital infections in patients with diabetes mellitus: beyond the conventional aspects. Int J Immunopathol Pharmacol . 2019;33:2058–2062. doi:10.1177/2058738419866582
   Web of Science ®Google Scholar
• Su H , Wan C , Song A , et al. Oxidative stress and renal fibrosis: mechanisms and therapies. Adv Exp Med Biol . 2019;1165:585–604.31399986
   PubMed Web of Science ®Google Scholar
• Davies MJ , D’Alessio DA , Fradkin J , et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care . 2018;41(12):2669–2701. doi:10.2337/dci18-0033 30291106
   PubMed Web of Science ®Google Scholar
• Neuen BL , Young T , Heerspink HJL , et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol . 2019;7(11):845–854. doi:10.1016/S2213-8587(19)30256-6 31495651
   PubMed Web of Science ®Google Scholar
• Menne J , Dumann E , Haller H , et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med . 2019;16(12):e1002983. doi:10.1371/journal.pmed.1002983 31815931
   PubMed Web of Science ®Google Scholar
• Zelniker TA , Wiviott SD , Raz I , et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet . 2019;393(10166):31–39. doi:10.1016/S0140-6736(18)32590-X 30424892
   PubMed Web of Science ®Google Scholar
• Buse JB , Wexler DJ , Tsapas A , et al. Correction to: 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia . 2020;63(8):1667. doi:10.1007/s00125-020-05151-2 32409867
   PubMed Web of Science ®Google Scholar
• Fernandez-Fernandez B , D’Marco L , Górriz JL , et al. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors for organ protection in COVID-19. J Clin Med . 2020;9(7):2030. doi:10.3390/jcm9072030
   Web of Science ®Google Scholar
• Mosley JF , Smith L , Everton E , et al. Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. PT . 2015;40(7):451–462.
   Google Scholar
• Baker ML , Perazella MA . SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern. J Nephrol . 2020;33(5):985–994. doi:10.1007/s40620-020-00712-5 32067179
   PubMed Web of Science ®Google Scholar
• Scheen AJ . An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf . 2019;18(4):295–311. doi:10.1080/14740338.2019.1602116 30933547
   PubMed Web of Science ®Google Scholar
• McGill JB , Subramanian S . Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol . 2019;124(Suppl 1):S45–S52. doi:10.1016/j.amjcard.2019.10.029 31741440
   PubMed Web of Science ®Google Scholar
• National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals . 8th ed. Washington (DC): National Academies Press (US); 2011.
   Google Scholar
• Hsia DS , Grove O , Cefalu WT . An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes . 2017;24(1):73–79. doi:10.1097/MED.0000000000000311 27898586
   PubMedGoogle Scholar
• van Raalte DH , Bjornstad P . Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes. Nephrol Dial Transplant . 2020;35(Suppl 1):i24–i32. doi:10.1093/ndt/gfz228 32003832
   PubMed Web of Science ®Google Scholar
• Rabizadeh S , Nakhjavani M , Esteghamati A . Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review. Int J Endocrinol Metab . 2019;17(2):e84353. doi:10.5812/ijem.84353 31372172
   PubMed Web of Science ®Google Scholar
• Ninčević V , Omanović Kolarić T , Roguljić H , et al. Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes. Int J Mol Sci . 2019;20(23):5831. doi:10.3390/ijms20235831
   Web of Science ®Google Scholar
• Pradhan A , Vohra S , Vishwakarma P , et al. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure. J Family Med Prim Care . 2019;8(6):1855–1862. doi:10.4103/jfmpc.jfmpc_232_19 31334145
   PubMedGoogle Scholar
• Williams DM , Evans M . Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-Preserved and EMPEROR-Reduced trials. Diabetes Ther . 2020;11(9):1925–1934. doi:10.1007/s13300-020-00889-9 32710261
   PubMed Web of Science ®Google Scholar
• Nadkarni GN , Ferrandino R , Chang A , et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care . 2017;40(11):1479–1485. doi:10.2337/dc17-1011 28827404
   PubMed Web of Science ®Google Scholar
• Iskander C , Cherney DZ , Clemens KK , et al. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. CMAJ . 2020;192(14):E351–E360. doi:10.1503/cmaj.191283 32392523
   PubMed Web of Science ®Google Scholar
• Novikov A , Vallon V . Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens . 2016;25(1):50–58. doi:10.1097/MNH.0000000000000187 26575393
   PubMed Web of Science ®Google Scholar
• Kalra S , Baruah MP , Sahay R . Medication counselling with sodium glucose transporter 2 inhibitor therapy. Indian J Endocrinol Metab . 2014;18(5):597–599. doi:10.4103/2230-8210.139206 25285273
   PubMedGoogle Scholar
• Raschi E , Poluzzi E , Fadini GP , et al. Observational research on sodium glucose co-transporter-2 inhibitors: a real breakthrough? Diabetes Obes Metab . 2018;20(12):2711–2723. doi:10.1111/dom.13468 30003655
   PubMed Web of Science ®Google Scholar